Palonosetron+Aprepitant+Dexamethasone for highly emetic chemotherapy induced nausea and voimiting

Palonosetron+Aprepitant+Dexamethasone for highly emetic chemotherapy induced nausea and voimiting - Palonosetron+Aprepitant+Dexamethasone for highly emetic chemotherapy induced nausea and voimiting

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004865

Enrollment

Registered

2011-01-13

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Aprepitant: 125mg po. 1-1.5 hr. prior to chemotherapy on Day1 PaIonosetron:0.75mg iv. prior to chemotherapy on Day1 Dexamethasone: 9.9mg iv. 30 min. prior to chemotherapy on Day 1, 8mg po. on Day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven Lung cancer 2)No prior chemotherapy 3)Patient receiving highly emetic chemotherapy defined by NCCN guideline 2009, ver 1. 3) Written IC.

Exclusion criteria

Exclusion criteria: 1) Vomiting prior to chemotherapy 2)HEC administration except Day 1. 3)Radiation therapy 4)Contraindication of Dexamethasone 5)Symptomatic brain meta 6)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone

Design outcomes

Primary

Measure	Time frame
Primary end point: Complete control rate	—

Secondary

Measure	Time frame
Secondary end point: Complete control rate, Time to treatment failure, QOL assessment.	—

Countries

Japan

Contacts

Public ContactHirohisa Yoshizawa

Niigata University Medical and Dental Hospital Bioscience Medical Research Center

hy0522@med.niigata-u.ac.jp025-227-2517

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026